Enrollment is complete for a Phase 2 trial testing Zenas Biopharma's obexelimab in relapsing MS, with results expected later ...

Columnist Ben Hofmeister is able to tell when people want the short answer to questions about his health. Too bad most MS answers are long.

Beneficiaries of plans that covered fewer than the median number of DMTs in the past year were more likely to have a relapse, ...

Columnist Desiree Lama has had to find some self-care strategies for managing her MS while also staying atop her work as a ...

Quantum signed a manufacturing agreement for the production of Lucid-MS as it prepares for a Phase 2 trial of the ...

People who develop MS begin using healthcare services more frequently up to 15 years before their MS symptoms first appear.

PET imaging using a novel tracer may help identify nerve damage in MS that can't be identified with conventional MRI imaging, ...

The experimental CAR T-cell therapy treatment was given as part of a clinical trial that's enrolling adults with progressive ...

Lucid-MS, Quantum Biopharma's oral multiple sclerosis therapy candidate, was not toxic and had no side effects in healthy ...

A study found neurofilament light chain at high levels in the blood and CSF of MS patients, suggesting its potential as a ...

Switching from one CD20-targeting therapy to another doesn't alter their ability to lower disease activity and slow ...

Columnist Desiree Lama describes her unexpected joy at having a new cat join her existing feline friend, especially when they ...